Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.81 USD | -2.43% | -3.10% | -51.55% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- Low profitability weakens the company.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-51.55% | 19.19M | B- | ||
+57.05% | 59.34B | B- | ||
+42.72% | 40.24B | A | ||
-5.39% | 39.88B | B | ||
-5.56% | 28.55B | C | ||
+15.76% | 27.26B | B- | ||
-21.16% | 19.23B | B | ||
+33.35% | 12.61B | C+ | ||
+3.30% | 12.49B | B+ | ||
+26.31% | 12.28B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MEIP Stock
- Ratings MEI Pharma, Inc.